Orforglipron Results: What Studies Measured and When
What published studies measured for Orforglipron, when those outcomes were measured, and what is still unproven.
What studies measured
Each outcome below comes from a published study, with its type and size, strongest design first. Animal and cell results are labelled as such and are not human results.
| Outcome | Result | Study type | Source |
|---|---|---|---|
| Body weight change | In people with diabetes, bodyweight changed by -5·1% (6 mg), -7·0% (12 mg) and -9·6% (36 mg) with orforglipron vs -2·5% with placebo at week 72. | Human RCTn = 1613 | Lancet 2026, PMID 41275875 |
| Glycaemic control vs oral semaglutide | Glycated hemoglobin changed by -1·71% (orforglipron 12 mg) and -1·91% (36 mg) vs -1·23% (semaglutide 7 mg) and -1·47% (14 mg) at week 52. | Human controlled trialn = 1698 | Lancet 2026, PMID 41765029 |
| Glycaemic control vs dapagliflozin | Glycated hemoglobin fell by 1·23%, 1·50% and 1·56% (orforglipron 3, 12, 36 mg) vs 0·81% with dapagliflozin 10 mg. | Human controlled trialn = 962 | Lancet 2026, PMID 42259339 |
| Maintenance of weight reduction after tirzepatide | After prior tirzepatide, orforglipron maintained an estimated 74.7% of body weight reduction vs 49.2% with placebo. | Human RCTn = 376 | Nature medicine 2026, PMID 42120723 |
| Maintenance of weight reduction after semaglutide | After prior semaglutide, orforglipron maintained an estimated 79.3% of body weight reduction vs 37.6% with placebo. | Human RCTn = 376 | Nature medicine 2026, PMID 42120723 |
| Weight change in older adults | In older adults without diabetes, weight changed by -7.9%, -11.3% and -13.0% with orforglipron vs -1.6% with placebo at week 72. | Human RCTn = 616 | Obesity pillars 2026, PMID 42577069 |
| Body weight change | Body weight changed by -7.5% (6 mg), -8.4% (12 mg) and -11.2% (36 mg) with orforglipron vs -2.1% with placebo at week 72. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Weight reduction thresholds at highest dose | In the 36-mg group, 54.6%, 36.0% and 18.4% lost at least 10%, 15% and 20% of body weight, vs 12.9%, 5.9% and 2.8% on placebo. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Cardiometabolic measures | Waist circumference, systolic blood pressure, triglycerides and non-HDL cholesterol significantly improved versus placebo. | Human RCTn = 3127 | The New England journal of medicine 2025, PMID 40960239 |
| Glycated hemoglobin change | Glycated hemoglobin fell by 1.24, 1.47 and 1.48 percentage points (3, 12, 36 mg) vs 0.41 with placebo at week 40. | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
| Body weight | Body weight changed by -4.5%, -5.8% and -7.6% (3, 12, 36 mg) vs -1.7% with placebo. | Human RCTn = 559 | The New England journal of medicine 2025, PMID 40544435 |
| Blood pressure, lipids and hsCRP | Blood pressure, LDL cholesterol, triglycerides, ApoB, ApoC3 and hsCRP decreased significantly versus placebo (exploratory analysis). | Human RCTn = 595 | Cardiovascular diabetology 2025, PMID 40481478 |
| Food effect on exposure | Exposure (AUC and Cmax) was lower by 23.7% and 23.2% in study A and by 17.6% and 20.9% in study B in the fed state. | Human RCTn = 46 | Diabetes therapy 2024, PMID 38402332 |
| Clinical relevance of food effect | The authors judged the food-related exposure differences unlikely to affect efficacy meaningfully. | Human RCTn = 46 | Diabetes therapy 2024, PMID 38402332 |
| Body weight change | Body weight changed by -8.6% to -12.6% at week 26 and -9.4% to -14.7% at week 36 with orforglipron, vs -2.0% and -2.3% with placebo. | Human RCTn = 272 | The New England journal of medicine 2023, PMID 37351564 |
| Glycaemic control and body weight | Glycated hemoglobin fell by up to 2·10% with orforglipron vs 0·43% with placebo and 1·10% with dulaglutide at week 26. | Human RCTn = 383 | Lancet 2023, PMID 37369232 |
| Short-term weight change | Body weight fell by up to 5.4 kg after 4 weeks with orforglipron vs 2.4 kg with placebo. | Human RCTn = 92 | Diabetes, obesity & metabolism 2023, PMID 37344954 |
| Glycated hemoglobin and weight | Glycated hemoglobin changed by -1.5% to -1.8% with orforglipron vs -0.4% with placebo; body weight changed by -0.24 to -5.8 kg vs 0.5 kg. | Human RCTn = 68 | Diabetes, obesity & metabolism 2023, PMID 37264711 |
| Absolute oral bioavailability | Mean absolute oral bioavailability of orforglipron was 79.1%. | Human uncontrolled trial | Clinical pharmacology in drug development 2026, PMID 40888509 |
| Route of elimination | Elimination was mainly via feces (87%) with minimal urinary excretion (0.2%). | Human uncontrolled trial | Clinical pharmacology in drug development 2026, PMID 40888509 |
| Weight loss | Versus placebo, orforglipron reduced body weight by 6.14 kg and waist circumference by 5.32 cm. | Meta-analysisn = 815 | Archives of endocrinology and metabolism 2024, PMID 39420937 |
- Foundayo (orforglipron) is on DailyMed (set id 8ac446c5, published 13 August 2026). The label's dose-escalation table is not reproduced here, so only administration, missed-dose and CYP3A4 limits are given.
Typical timeline
When the studies above measured their outcomes. This is the study schedule, not a promise of when anyone will notice a change.
| When | What was measured | Study type | Source |
|---|---|---|---|
| Week 26 | Primary weight outcome | Human RCTn = 272 | The New England journal of medicine 2023, PMID 37351564 |
Before-and-after photos
We don't publish before-and-after photos. They can't be verified, rarely show dose, diet or other drugs, and only the most dramatic results get posted.
Common questions
How long does Orforglipron take to work?
The studies we summarise measured outcomes at set points, for example Primary weight outcome at Week 26. Timelines outside studies vary.
Do you show Orforglipron before and after photos?
No. Photos can't be verified, rarely show dose, diet or other drugs, and only the most dramatic ones get posted. We summarize measured outcomes instead.
More on Orforglipron
DosageDoses used in published studies, with the source for each.Side effectsWhat labels and studies report, and what is unknown.PricePrice per mg and per week from dated listings. No vendor links.Legal statusFDA, compounding and WADA status with dates.For weight lossWhat research says about Orforglipron for weight loss.
Sources
- 1Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial.Lancet (London, England) · 2026PMID 41275875Accessed 2 Oct 2026
- 2Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.Lancet (London, England) · 2026PMID 41765029Accessed 2 Oct 2026
- 3Orforglipron compared with dapagliflozin in adults with type 2 diabetes and inadequate glycaemic control with metformin (ACHIEVE-2): a multicentre, randomised, non-inferiority, open-label, phase 3 trial.Lancet (London, England) · 2026PMID 42259339Accessed 2 Oct 2026
- 4Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.Nature medicine · 2026PMID 42120723Accessed 2 Oct 2026
- 5Orforglipron for obesity treatment in older patients ≥65 years with or without type 2 diabetes: A post hoc subgroup analysis of the ATTAIN-1 and ATTAIN-2 trials.Obesity pillars · 2026PMID 42577069Accessed 2 Oct 2026
- 6Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment.The New England journal of medicine · 2025PMID 40960239Accessed 2 Oct 2026
- 7Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.The New England journal of medicine · 2025PMID 40544435Accessed 2 Oct 2026
- 8Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.Cardiovascular diabetology · 2025PMID 40481478Accessed 2 Oct 2026
- 9Effect of Food Consumption on the Pharmacokinetics, Safety, and Tolerability of Once-Daily Orally Administered Orforglipron (LY3502970), a Non-peptide GLP-1 Receptor Agonist.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024PMID 38402332Accessed 2 Oct 2026
- 10Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.The New England journal of medicine · 2023PMID 37351564Accessed 2 Oct 2026
- 11Efficacy and safety of oral orforglipron in patients with type 2 diabetes: a multicentre, randomised, dose-response, phase 2 study.Lancet (London, England) · 2023PMID 37369232Accessed 2 Oct 2026
- 12Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.Diabetes, obesity & metabolism · 2023PMID 37344954Accessed 2 Oct 2026
- 13Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.Diabetes, obesity & metabolism · 2023PMID 37264711Accessed 2 Oct 2026
- 14Disposition and Absolute Bioavailability of Orally Administered Orforglipron in Healthy Participants.Clinical pharmacology in drug development · 2026PMID 40888509Accessed 2 Oct 2026
- 15Effects of once-daily oral orforglipron on weight and metabolic markers: a systematic review and meta-analysis of randomized controlled trials.Archives of endocrinology and metabolism · 2024PMID 39420937Accessed 2 Oct 2026
Found an error? Report a correction.